ArticlePloS one2011
Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Treatment of diabetic retinopathy through neuropeptide Y-mediated enhancement of neurovascular microenvironment.Journal of cellular and molecular medicine · 2020Article
- Placental growth factor negatively regulates retinal endothelial cell barrier function through suppression of glucose-6-phosphate dehydrogenase and antioxidant defense systems.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Restoring retinal neurovascular health via substance P.Experimental cell research · 2019Article
- Regulation of human feto-placental endothelial barrier integrity by vascular endothelial growth factors: competitive interplay between VEGF-AClinical science (London, England : 1979) · 2017Article
- Characterization of zofenoprilat as an inducer of functional angiogenesis through increased H2 S availability.British journal of pharmacology · 2015Article
- Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2015Article
- Modulation of VEGF-induced retinal vascular permeability by peroxisome proliferator-activated receptor-β/δ.Investigative ophthalmology & visual science · 2014Article
- Ranibizumab efficiently blocks migration but not proliferation induced by growth factor combinations including VEGF in retinal endothelial cells.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2013Article
- Circulating mononuclear progenitor cells: differential roles for subpopulations in repair of retinal vascular injury.Investigative ophthalmology & visual science · 2013Article
- Angiopoietin-2 is vasoprotective in the acute phase of cerebral ischemia.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2013Article
- β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment.EMBO molecular medicine · 2012Article
- Vascular adaptation to a dysfunctional endothelium as a consequence of Shb deficiency.Angiogenesis · 2012Article
- PlGF: a multitasking cytokine with disease-restricted activity.Cold Spring Harbor perspectives in medicine · 2012Review
- Diabetic macular edema: current and emerging therapies.Middle East African journal of ophthalmology · 2012Article
- Article
- γ-Secretase and presenilin mediate cleavage and phosphorylation of vascular endothelial growth factor receptor-1.The Journal of biological chemistry · 2011Article
- Free insulin-like growth factor binding protein-3 (IGFBP-3) reduces retinal vascular permeability in association with a reduction of acid sphingomyelinase (ASMase).Investigative ophthalmology & visual science · 2011Article
- RPE barrier breakdown in diabetic retinopathy: seeing is believing.Journal of ocular biology, diseases, and informatics · 2011Article
- Article
- Article
Corrections and comments
- Retraction · 2019-01-16Concerns/Issues about Data · Duplication of/in Image ·
- Retracted
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
Abstract
Increased vascular permeability is an early event characteristic of tissue ischemia and angiogenesis. Although VEGF family members are potent promoters of endothelial permeability the role of placental growth factor (PlGF) is hotly debated. Here we investigated PlGF isoforms 1 and 2 and present in vitro and in vivo evidence that PlGF-1, but not PlGF-2, can inhibit VEGF-induced permeability but only during a critical window post-VEGF exposure. PlGF-1 promotes VE-cadherin expression via the trans-activating Sp1 and Sp3 interaction with the VE-cadherin promoter and subsequently stabilizes transendothelial junctions, but only after activation of endothelial cells by VEGF. PlGF-1 regulates vascular permeability associated with the rapid localization of VE-cadherin to the plasma membrane and dephosphorylation of tyrosine residues that precedes changes observed in claudin 5 tyrosine phosphorylation and membrane localization. The critical window during which PlGF-1 exerts its effect on VEGF-induced permeability highlights the importance of the translational significance of this work in that PLGF-1 likely serves as an endogenous anti-permeability factor whose effectiveness is limited to a precise time point following vascular injury. Clinical approaches that would pattern nature's approach would thus limit treatments to precise intervals following injury and bring attention to use of agents only during therapeutic windows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.